FWIA
ESPR

Fort Washington Investment Advisors’s Esperion Therapeutics ESPR Stock Holding History

Fort Washington Investment Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-58,636
Closed -$886K – 435
2014
Q1 		$886K Buy
+58,636
New +$910K 0.02% 272

Other funds holding ESPR

AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fort Washington Investment Advisors's ESPR Position: Q2 2014 in Review

Fort Washington Investment Advisors sold out of Esperion Therapeutics (ESPR) in Q2 2014, closing a stake of 58,636 shares — an estimated $886K sold.

Fort Washington Investment Advisors first reported a position in ESPR in Q1 2014 and held it in 1 quarter. The position peaked at $886K in Q1 2014. 43 funds tracked by Wall St. Rank hold ESPR as of Q2 2014.

  • Fort Washington Investment Advisors reported no remaining Esperion Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Fort Washington Investment Advisors sold 58,636 Esperion Therapeutics shares in Q2 2014, an estimated $886K.
  • Fort Washington Investment Advisors first reported a position in Esperion Therapeutics in Q1 2014 and held it in 1 quarter.
  • Fort Washington Investment Advisors's Esperion Therapeutics position peaked at $886K in Q1 2014.
  • 43 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2014.

Based on Fort Washington Investment Advisors's 13F filing for Q2 2014, filed 14 Aug 2014.